IRONWOOD PHARMACEUTICALS, INC. Net Income (Loss) Available to Common Stockholders, Diluted
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Net Income (Loss) Available to Common Stockholders, Diluted of $51.29 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-06
- IRONWOOD PHARMACEUTICALS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was $51.29M, a 111.15% increase year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was $40.77M.
- IRONWOOD PHARMACEUTICALS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-12-31 was -$4.35M, a 292.91% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was $40.77M, a 1018.29% increase year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. net income (loss) available to common stockholders, diluted for fiscal 2025 was $24.02M, a 2629.20% increase from fiscal 2024.
- IRONWOOD PHARMACEUTICALS, INC. net income (loss) available to common stockholders, diluted for fiscal 2024 was $880.00K.
- IRONWOOD PHARMACEUTICALS, INC. net income (loss) available to common stockholders, diluted for fiscal 2023 was -$1.00B, a 658.31% decline from fiscal 2022.
- IRONWOOD PHARMACEUTICALS, INC. net income (loss) available to common stockholders, diluted for fiscal 2022 was $179.51M, a 10.64% increase from fiscal 2021.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $51.29M 10-Q · filed 2026-08-06 | $92.06M 10-Q · filed 2026-08-06 | $87.71M derived: sum of 3 quarters · filed 2026-08-06 | $128.49M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $40.77M 10-Q · filed 2026-05-07 | $36.42M derived: sum of 2 quarters · filed 2026-05-07 | $77.19M derived: sum of 3 quarters · filed 2026-05-07 | $101.48M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | -$4.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $36.42M derived: sum of 2 quarters · filed 2026-02-26 | $60.71M derived: sum of 3 quarters · filed 2026-08-06 | $24.02M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $40.77M 10-Q · filed 2025-11-10 | $65.06M derived: sum of 2 quarters · filed 2026-08-06 | $28.37M 10-Q · filed 2025-11-10 | $29.93M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $24.29M 10-Q · filed 2026-08-06 | -$13.79M 10-Q · filed 2026-08-06 | -$10.84M derived: sum of 3 quarters · filed 2026-08-06 | -$7.19M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | -$37.39M 10-Q · filed 2026-05-07 | -$35.13M derived: sum of 2 quarters · filed 2026-05-07 | -$31.48M derived: sum of 3 quarters · filed 2026-05-07 | -$32.34M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $2.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.90M derived: sum of 2 quarters · filed 2026-02-26 | $5.04M derived: sum of 3 quarters · filed 2026-02-26 | $880.00K 10-K · filed 2026-02-26 | |
| 2024-09-30 | $3.65M 10-Q · filed 2025-11-10 | $2.79M derived: sum of 2 quarters · filed 2025-11-10 | -$1.38M 10-Q · filed 2025-11-10 | -$2.46M derived: sum of 4 quarters · filed 2025-11-10 | |
| 2024-06-30 | -$860.00K 10-Q · filed 2025-08-11 | -$5.02M 10-Q · filed 2025-08-11 | -$6.11M derived: sum of 3 quarters · filed 2025-08-11 | $10.33M derived: sum of 4 quarters · filed 2025-08-11 | |
| 2024-03-31 | -$4.16M 10-Q · filed 2024-05-09 | -$5.25M derived: sum of 2 quarters · filed 2025-03-31 | $11.19M derived: sum of 3 quarters · filed 2025-03-31 | -$1.05B derived: sum of 4 quarters · filed 2025-03-31 | |
| 2023-12-31 | -$1.09M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $15.35M derived: sum of 2 quarters · filed 2025-03-31 | -$1.05B derived: sum of 3 quarters · filed 2025-03-31 | -$1.00B 10-K · filed 2025-03-31 | $155.44M 10-K · filed 2024-02-16 |
| 2023-09-30 | $16.44M 10-Q · filed 2024-11-07 | -$1.05B derived: sum of 2 quarters · filed 2024-11-07 | -$1.00B 10-Q · filed 2024-11-07 | -$948.94M derived: sum of 4 quarters · filed 2025-03-31 | |
| 2023-06-30 | -$1.06B 10-Q · filed 2023-08-09 | -$1.02B 10-Q · filed 2023-08-09 | -$965.38M derived: sum of 3 quarters · filed 2025-03-31 | -$913.95M derived: sum of 4 quarters · filed 2025-03-31 | |
| 2023-03-31 | $46.83M 10-Q · filed 2024-05-09 | $96.81M derived: sum of 2 quarters · filed 2025-03-31 | $148.24M derived: sum of 3 quarters · filed 2025-03-31 | $186.43M derived: sum of 4 quarters · filed 2025-03-31 | |
| 2022-12-31 | $49.98M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $101.41M derived: sum of 2 quarters · filed 2025-03-31 | $139.60M derived: sum of 3 quarters · filed 2025-03-31 | $179.51M 10-K · filed 2025-03-31 | |
| 2022-09-30 | $51.43M 10-Q · filed 2023-11-09 | $89.62M derived: sum of 2 quarters · filed 2023-11-09 | $129.53M 10-Q · filed 2023-11-09 | -$195.30M derived: sum of 4 quarters · filed 2024-02-16 | |
| 2022-06-30 | $38.19M 10-Q · filed 2023-08-09 | $78.10M 10-Q · filed 2023-08-09 | -$246.73M derived: sum of 3 quarters · filed 2024-02-16 | -$190.88M derived: sum of 4 quarters · filed 2024-02-16 | |
| 2022-03-31 | $39.91M 10-Q · filed 2023-05-04 | -$284.92M derived: sum of 2 quarters · filed 2024-02-16 | -$229.07M derived: sum of 3 quarters · filed 2024-02-16 | $162.23M derived: sum of 4 quarters · filed 2024-02-16 | |
| 2021-12-31 | -$324.83M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-16 | -$268.98M derived: sum of 2 quarters · filed 2024-02-16 | $122.32M derived: sum of 3 quarters · filed 2024-02-16 | $162.25M 10-K · filed 2024-02-16 | $528.45M 10-K · filed 2022-02-18 |
| 2021-09-30 | $55.84M 10-Q · filed 2022-11-03 | $447.15M derived: sum of 2 quarters · filed 2022-11-03 | $487.07M 10-Q · filed 2022-11-03 | $530.28M derived: sum of 4 quarters · filed 2023-02-16 | |
| 2021-06-30 | $391.30M 10-Q · filed 2022-08-04 | $431.23M 10-Q · filed 2022-08-04 | $474.43M derived: sum of 3 quarters · filed 2023-02-16 | $508.86M derived: sum of 4 quarters · filed 2023-02-16 | |
| 2021-03-31 | $39.93M 10-Q · filed 2022-05-05 | $83.13M derived: sum of 2 quarters · filed 2023-02-16 | $117.55M derived: sum of 3 quarters · filed 2023-02-16 | $142.76M derived: sum of 4 quarters · filed 2023-02-16 | |
| 2020-12-31 | $43.20M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-16 | $77.63M derived: sum of 2 quarters · filed 2023-02-16 | $102.83M derived: sum of 3 quarters · filed 2023-02-16 | $106.18M 10-K · filed 2023-02-16 | |
| 2020-09-30 | $34.42M 10-Q · filed 2021-11-04 | $59.63M derived: sum of 2 quarters · filed 2021-11-04 | $62.97M 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | $25.20M 10-Q · filed 2021-08-05 | $28.55M 10-Q · filed 2021-08-05 | |||
| 2020-03-31 | $3.35M 10-Q · filed 2021-05-06 | ||||
| 2019-12-31 | $21.50M 10-K · filed 2022-02-18 | ||||
| 2018-12-31 | -$282.37M 10-K · filed 2021-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |